Search Results - "Tiffany, Courtney A"

Gepotidacin for the Treatment of Uncomplicated Urogenital Gonorrhea: A Phase 2, Randomized, Dose-Ranging, Single-Oral Dose Evaluation by Taylor, Stephanie N, Morris, David H, Avery, Ann K, Workowski, Kimberly A, Batteiger, Byron E, Tiffany, Courtney A, Perry, Caroline R, Raychaudhuri, Aparna, Scangarella-Oman, Nicole E, Hossain, Mohammad, Dumont, Etienne F

“…In this phase 2 study, single oral doses of gepotidacin were ≥95% effective for bacterial eradication in culture-proven uncomplicated urogenital gonorrhea. New…”
Get full text

Phase 2a Pharmacokinetic, Safety, and Exploratory Efficacy Evaluation of Oral Gepotidacin (GSK2140944) in Female Participants With Uncomplicated Urinary Tract Infection (Acute Uncomplicated Cystitis) by Overcash, J Scott, Tiffany, Courtney A, Scangarella-Oman, Nicole E, Perry, Caroline R, Tao, Yu, Hossain, Mohammad, Barth, Aline, Dumont, Etienne F

“…Gepotidacin, a triazaacenaphthylene bacterial type II topoisomerase inhibitor, is in development for treatment of uncomplicated urinary tract infection (uUTI)…”
Get full text

Microbiological Analysis from a Phase 2 Randomized Study in Adults Evaluating Single Oral Doses of Gepotidacin in the Treatment of Uncomplicated Urogenital Gonorrhea Caused by Neisseria gonorrhoeae by Scangarella-Oman, Nicole E, Hossain, Mohammad, Dixon, Paula B, Ingraham, Karen, Min, Sharon, Tiffany, Courtney A, Perry, Caroline R, Raychaudhuri, Aparna, Dumont, Etienne F, Huang, Jianzhong, Hook, 3rd, Edward W, Miller, Linda A

“…We evaluated microbiological correlates for the successful treatment of isolates from a phase 2 study of gepotidacin, a novel triazaacenaphthylene…”
Get full text

Pharmacokinetics of Oral Formulations of Gepotidacin (GSK2140944), a Triazaacenaphthylene Bacterial Type II Topoisomerase Inhibitor, in Healthy Adult and Adolescent Participants by Barth, Aline, Hossain, Mohammad, Brimhall, Darin B, Perry, Caroline R, Tiffany, Courtney A, Xu, Sherry, Dumont, Etienne F

“…Gepotidacin is a novel, first-in-class triazaacenaphthylene antibiotic that may provide a new treatment option for antibiotic-resistant pathogens. Two…”
Get full text

In Vitro Activity and Microbiological Efficacy of Gepotidacin from a Phase 2, Randomized, Multicenter, Dose-Ranging Study in Patients with Acute Bacterial Skin and Skin Structure Infections by Scangarella-Oman, Nicole E, Ingraham, Karen A, Tiffany, Courtney A, Tomsho, Lynn, Van Horn, Stephanie F, Mayhew, David N, Perry, Caroline R, Ashton, Theresa C, Dumont, Etienne F, Huang, Jianzhong, Brown, James R, Miller, Linda A

“…A phase 2 study of gepotidacin demonstrated the safety and efficacy of 3 gepotidacin doses (750 mg every 12 h [q12h], 1,000 mg q12h, and 1,000 mg every 8 h…”
Get full text

Pharmacokinetics, Safety, and Tolerability Evaluation of Single and Multiple Doses of GSK3342830 in Healthy Volunteers by Tenero, David, Farinola, Nicholas, Berkowitz, Elchonon M., Tiffany, Courtney A., Qian, Yanwen, Xue, Zhengyu, Raychaudhuri, Aparna, Gardiner, David F.

“…This was a first‐time‐in‐human randomized, double‐blind, single‐center, placebo‐controlled dose‐escalation study to determine the safety, tolerability, and…”
Get full text